Ceruvia Lifesciences
✓ Verified ManufacturerAbout
Ceruvia Lifesciences is a pioneering neurotransformational medicine company headquartered in Greenwich, Connecticut, dedicated to developing innovative treatments for challenging psychiatric and neurological disorders. Founded in 2017 by CEO Carey Turnbull, the company specializes in transforming psychedelic research into cutting-edge pharmaceutical solutions for patients suffering from hard-to-treat conditions including obsessive-compulsive disorder, cluster headaches, migraines, and various mental health disorders. The company operates state-of-the-art manufacturing facilities that produce pharmaceutical-grade psychedelic compounds meeting stringent Current Good Manufacturing Practices standards required by the FDA. Ceruvia has achieved a significant milestone as the producer of the world's first LSD that meets CGMP standards, which they offer to qualified researchers at no cost to advance scientific understanding. Their primary therapeutic compounds include synthetic psilocybin and BOL-148, a non-hallucinogenic analog of LSD. With over a decade of experience in psychedelic research and strategic partnerships with prestigious institutions including Yale University School of Medicine, NYU School of Medicine, and Harvard Medical School, Ceruvia Lifesciences maintains rigorous clinical development programs. The company has submitted FDA Investigational New Drug applications and is advancing Phase 2 clinical trials, positioning them at the forefront of the emerging psychedelic medicine sector while delivering hope to patients with treatment-resistant conditions.